Exact Mass: 492.2478
Exact Mass Matches: 492.2478
Found 276 metabolites which its exact mass value is equals to given mass value 492.2478
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Bezitramide
N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AC - Diphenylpropylamine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics
Lurasidone
Vorapaxar
PA(2:0/18:1(12Z)-O(9S,10R))
PA(2:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(12Z)-O(9S,10R)/2:0)
PA(18:1(12Z)-O(9S,10R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/2:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/18:1(9Z)-O(12,13))
PA(2:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(9Z)-O(12,13)/2:0)
PA(18:1(9Z)-O(12,13)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/2:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Kushenol B
Kushenol B is a member of flavanones. Kushenol B is a natural product found in Sophora and Sophora flavescens with data available.
Kadlongilactone B
A hexacyclic triterpenoid isolated from the leaves and stems of Kadsura longipedunculata and has been found to exhibit cytotoxicity aganist human tumour cells.
Macaflavanone G
A trihydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 5, 7 and 4, a prenyl group at position 6 and a (2S)-2-methyl-2-(4-methylpent-3-en-1-yl)tetrahydro-2H-pyran ring fused across positions 2 and 3. Isolated from the leaves of Macaranga tanarius, it exhibits antineoplastic activity.
2,4,6,3-Tetrahydroxy-3-geranyl-6,6-dimethylpyrano[2,3:4,5]dihydrochalcone
Propolin G
(-)-Nymphaeol C|(-)-Nymphaeol-C|5,7,3,4-tetrahydroxy-6-(3,3-dimethylallyl)-2-C-geranylflavanone|5,7,3,4-tetrahydroxy-6-(3,3-dimethylallyl)-2-geranylflavanone|Nymphaeol C|nymphaeol-C|propolin G
(E)-1,3-dihydroxy-6,7-dimethoxy-2-(3-methylbut-2-enyl)-8-(3,7-dimethyl-2,6-octadienyl)xanthone|6-O-methylcowanin
lespeflorin B4
A trihydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 3, 5, 7 and 4 and prenyl groups at positions 6, 8 and 3. Isolated from the roots of Lespedeza floribunda, it acts as a melanin synthesis inhibitor.
Sanggenol P
5,7,2,4-tetrahydroxyl-6,8,5-tri-(gamma,gamma-dimethylallyl)isoflavanone|6,8,5-tri-(gamma,gamma-dimethylallyl)dalbergioidin|ormosinol
Cys Lys Arg Ser
Cys Lys Ser Arg
Cys Arg Lys Ser
Cys Arg Ser Lys
Cys Ser Lys Arg
Cys Ser Arg Lys
Phe Gly Asn Arg
Phe Gly Arg Asn
Phe Met Pro Val
Phe Met Val Pro
Phe Asn Gly Arg
Phe Asn Arg Gly
Phe Pro Met Val
Phe Pro Val Met
Phe Arg Gly Asn
Phe Arg Asn Gly
Phe Val Met Pro
Phe Val Pro Met
Gly Phe Asn Arg
Gly Phe Arg Asn
Gly Asn Phe Arg
Gly Asn Arg Phe
Gly Arg Phe Asn
Gly Arg Asn Phe
His His Ile Ser
His His Leu Ser
His His Ser Ile
His His Ser Leu
His His Thr Val
His His Val Thr
His Ile His Ser
His Ile Ser His
His Leu His Ser
His Leu Ser His
His Ser His Ile
His Ser His Leu
His Ser Ile His
His Ser Leu His
His Thr His Val
His Thr Val His
His Val His Thr
His Val Thr His
Ile His His Ser
Ile His Ser His
Ile Met Met Val
Ile Met Val Met
Ile Ser His His
Ile Val Met Met
Lys Cys Arg Ser
Lys Cys Ser Arg
Lys Arg Cys Ser
Lys Arg Ser Cys
Lys Ser Cys Arg
Lys Ser Arg Cys
Leu His His Ser
Leu His Ser His
Leu Met Met Val
Leu Met Val Met
Leu Ser His His
Leu Val Met Met
Met Phe Pro Val
Met Phe Val Pro
Met Ile Met Val
Met Ile Val Met
Met Leu Met Val
Met Leu Val Met
Met Met Ile Val
Met Met Leu Val
Met Met Val Ile
Met Met Val Leu
Met Pro Phe Val
Met Pro Val Phe
Met Val Phe Pro
Met Val Ile Met
Met Val Leu Met
Met Val Met Ile
Met Val Met Leu
Met Val Pro Phe
Asn Phe Gly Arg
Asn Phe Arg Gly
Asn Gly Phe Arg
Asn Gly Arg Phe
Asn Arg Phe Gly
Asn Arg Gly Phe
Pro Phe Met Val
Pro Phe Val Met
Pro Met Phe Val
Pro Met Val Phe
Pro Val Phe Met
Pro Val Met Phe
Arg Cys Lys Ser
Arg Cys Ser Lys
Arg Phe Gly Asn
Arg Phe Asn Gly
Arg Gly Phe Asn
Arg Gly Asn Phe
Arg Lys Cys Ser
Arg Lys Ser Cys
Arg Asn Phe Gly
Arg Asn Gly Phe
Arg Ser Cys Lys
Arg Ser Lys Cys
Ser Cys Lys Arg
Ser Cys Arg Lys
Ser His His Ile
Ser His His Leu
Ser His Ile His
Ser His Leu His
Ser Ile His His
Ser Lys Cys Arg
Ser Lys Arg Cys
Ser Leu His His
Ser Arg Cys Lys
Ser Arg Lys Cys
Thr His His Val
Thr His Val His
Thr Val His His
Val Phe Met Pro
Val Phe Pro Met
Val His His Thr
Val His Thr His
Val Ile Met Met
Val Leu Met Met
Val Met Phe Pro
Val Met Ile Met
Val Met Leu Met
Val Met Met Ile
Val Met Met Leu
Val Met Pro Phe
Val Pro Phe Met
Val Pro Met Phe
Val Thr His His
29-demethylgeodisterol-O-sulfite
Vorapaxar
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C78274 - Agent Affecting Cardiovascular System COVID info from Guide to PHARMACOLOGY Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
lurasidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AE - Indole derivatives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate
Bezitramide
N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AC - Diphenylpropylamine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics
ethyl N-[9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
[(2R)-1-acetyloxy-3-phosphonooxypropan-2-yl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
[(2R)-2-acetyloxy-3-phosphonooxypropyl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
Nymphaeol C
A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy group at positions 5, 7, 3 and 4, a geranyl group at position 2 and a prenyl group at position 6. Isolated from Macaranga tanarius and propolis collected in Okinawa, it exhibits radical scavenging activity.
schizolaenone B
A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 5, 7, 4 and 5, a geranyl group at position 3 and a prenyl group at position 6. Isolated from Schizolaena hystrix, it exhibits cytotoxicity against ovarian cancer cell line.
3-[[4-(diphenylmethyl)-1-piperazinyl]-oxomethyl]-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-12-one
3-[(1-tert-butyl-5-tetrazolyl)-[2-furanylmethyl(2-oxolanylmethyl)amino]methyl]-6-methoxy-1H-quinolin-2-one
(2S,3S,3aR,9bR)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(2R,3R,3aS,9bS)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(1S)-1-(hydroxymethyl)-7-methoxy-1-[oxo(2-pyrazinyl)methyl]-N-propan-2-yl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1R)-2-(cyclopropylmethyl)-N-(3-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1S)-2-(cyclopropylmethyl)-N-(3-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1R)-1-(hydroxymethyl)-7-methoxy-1-[oxo(2-pyrazinyl)methyl]-N-propan-2-yl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(2R,3R,3aS,9bS)-1-N-cyclopentyl-3-(hydroxymethyl)-6-oxo-7-[(E)-prop-1-enyl]-2-N-(pyrimidin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(2S,3S,3aR,9bR)-1-N-cyclopentyl-3-(hydroxymethyl)-6-oxo-7-[(E)-prop-1-enyl]-2-N-(pyrimidin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
5',9,9,14,18-pentamethyl-3'h-8,20,24-trioxaspiro[hexacyclo[19.2.1.0²,¹³.0⁴,¹⁰.0¹⁴,²².0¹⁷,²²]tetracosane-19,2'-pyran]-2(13),3,5-triene-6',7-dione
3,8,9-trihydroxy-4-[4-hydroxy-3-(hydroxymethyl)but-2-en-1-yl]-6-methyl-4,7-bis(3-methylbut-2-en-1-yl)anthracen-1-one
(1s,10r,14s,17r,18s,19s,21r,22s)-5',9,9,14,18-pentamethyl-3'h-8,20,24-trioxaspiro[hexacyclo[19.2.1.0²,¹³.0⁴,¹⁰.0¹⁴,²².0¹⁷,²²]tetracosane-19,2'-pyran]-2(13),3,5-triene-6',7-dione
2-[2-(3,7-dimethylocta-2,6-dien-1-yl)-3,4-dihydroxyphenyl]-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2s)-2-[5-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxyphenyl]-5,7-dihydroxy-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(1s,1'r,2s,3's,5s,6's,9s,10's,11'r,12r,14s)-2-hydroxy-2,3',11,12'-tetramethyl-6-methylidene-2',8,9'-trioxaspiro[tetracyclo[10.2.1.0¹,¹⁰.0⁵,⁹]pentadecane-14,7'-tetracyclo[9.3.0.0¹,³.0⁶,¹⁰]tetradecane]-10,12'-diene-7,8'-dione
(2s)-5,7-dihydroxy-2-[(2r)-8-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)-3,4-dihydro-1-benzopyran-6-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(1r,2s,13r,15r,18s,23s,24s)-13-hydroxy-1,6,6,20,24-pentamethyl-7,22-dioxahexacyclo[13.12.0.0²,¹³.0⁵,¹¹.0¹⁶,²⁵.0¹⁸,²³]heptacosa-9,11,16(25),19-tetraene-8,21,26-trione
(10s)-4,10,15-trihydroxy-13-methyl-5,7-bis(3-methylbut-2-en-1-yl)-12-[(3-methylbut-2-en-1-yl)oxy]-9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-2-one
artemyriantholide a
{"Ingredient_id": "HBIN016967","Ingredient_name": "artemyriantholide a","Alias": "NA","Ingredient_formula": "C30H36O6","Ingredient_Smile": "CC1=CCC23C1C4C(CCC2(O3)C)C5(CC6CC57C(=C6C)C8C(CCC7(C)O)C(=C)C(=O)O8)C(=O)O4","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1803","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
artemyriantholide b
{"Ingredient_id": "HBIN016968","Ingredient_name": "artemyriantholide b","Alias": "NA","Ingredient_formula": "C30H36O6","Ingredient_Smile": "CC1=CCC23C1C4C(CCC2(O3)C)C5(CC6CC57C(=C6C)C8C(CCC7(C)O)C(=C)C(=O)O8)C(=O)O4","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1804","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
artemyriantholide d
{"Ingredient_id": "HBIN016970","Ingredient_name": "artemyriantholide d","Alias": "NA","Ingredient_formula": "C30H36O6","Ingredient_Smile": "CC1=CCC23C1C4C(CCC2(O3)C)C5(CC67C=CC5(C6C8C(CCC7(C)O)C(=C)C(=O)O8)C)C(=O)O4","Ingredient_weight": "492.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1806","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "21668651","DrugBank_id": "NA"}